Join
Live feed
·
INSIDERFilingvia Quantisnow
Spyre Therapeutics Inc. logo

Director Henderson Michael Thomas sold $5,952,050 worth of shares (80,000 units at $74.40) as part of a pre-agreed trading plan, decreasing direct ownership by 47% to 88,606 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
SYRE· Spyre Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SYRE (Spyre Therapeutics Inc.) and more on Quantisnow.